GIP/GLP1 CO-AGONIST COMPOUNDS
To provide compounds that have agonist activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and are suitable for oral administration.SOLUTION: The present invention provides a compound having a specific amino acid sequence or a p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | QU HONGCHANG JORGE ALSINA-FERNANDEZ FRANCIS STAFFORD WILLARD JAMES LINCOLN WALLIS COSKUN TAMER OVER CABRERA ROBERT CHADWICK CUMMINS AKTHAM ABURUB KYLE WYNN SLOOP ROBERT ANDREW BROWN MOHAMED ELSAYED HAMED ELSAYED MILATA MARY ABRAHAM PHENIL JAYANTILAL PATEL THI THANH HUYEN TRAN AMITA DATTA-MANNAN LAI XIANYIN |
| description | To provide compounds that have agonist activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and are suitable for oral administration.SOLUTION: The present invention provides a compound having a specific amino acid sequence or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
【課題】ヒトグルコース依存性インスリン分泌刺激ポリペプチド（ＧＩＰ）受容体およびグルカゴン様ペプチド－１（ＧＬＰ－１）受容体でアゴニスト活性を有する、経口投与に適した化合物を提供する。【解決手段】特定のアミノ酸配列を有する化合物、またはその薬学的に許容可能な塩による。【選択図】なし |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2023171775A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2023171775A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2023171775A3</originalsourceid><addsrcrecordid>eNrjZJB19wzQd_cJMFRw9td1dPf38wwOATJ9A_xD_VyCeRhY0xJzilN5oTQ3g5Kba4izh25qQX58anFBYnJqXmpJvFeAkYGRsaG5obm5qaMxUYoAxDohbQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GIP/GLP1 CO-AGONIST COMPOUNDS</title><source>esp@cenet</source><creator>QU HONGCHANG ; JORGE ALSINA-FERNANDEZ ; FRANCIS STAFFORD WILLARD ; JAMES LINCOLN WALLIS ; COSKUN TAMER ; OVER CABRERA ; ROBERT CHADWICK CUMMINS ; AKTHAM ABURUB ; KYLE WYNN SLOOP ; ROBERT ANDREW BROWN ; MOHAMED ELSAYED HAMED ELSAYED ; MILATA MARY ABRAHAM ; PHENIL JAYANTILAL PATEL ; THI THANH HUYEN TRAN ; AMITA DATTA-MANNAN ; LAI XIANYIN</creator><creatorcontrib>QU HONGCHANG ; JORGE ALSINA-FERNANDEZ ; FRANCIS STAFFORD WILLARD ; JAMES LINCOLN WALLIS ; COSKUN TAMER ; OVER CABRERA ; ROBERT CHADWICK CUMMINS ; AKTHAM ABURUB ; KYLE WYNN SLOOP ; ROBERT ANDREW BROWN ; MOHAMED ELSAYED HAMED ELSAYED ; MILATA MARY ABRAHAM ; PHENIL JAYANTILAL PATEL ; THI THANH HUYEN TRAN ; AMITA DATTA-MANNAN ; LAI XIANYIN</creatorcontrib><description>To provide compounds that have agonist activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and are suitable for oral administration.SOLUTION: The present invention provides a compound having a specific amino acid sequence or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
【課題】ヒトグルコース依存性インスリン分泌刺激ポリペプチド（ＧＩＰ）受容体およびグルカゴン様ペプチド－１（ＧＬＰ－１）受容体でアゴニスト活性を有する、経口投与に適した化合物を提供する。【解決手段】特定のアミノ酸配列を有する化合物、またはその薬学的に許容可能な塩による。【選択図】なし</description><language>eng ; jpn</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231205&DB=EPODOC&CC=JP&NR=2023171775A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231205&DB=EPODOC&CC=JP&NR=2023171775A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>QU HONGCHANG</creatorcontrib><creatorcontrib>JORGE ALSINA-FERNANDEZ</creatorcontrib><creatorcontrib>FRANCIS STAFFORD WILLARD</creatorcontrib><creatorcontrib>JAMES LINCOLN WALLIS</creatorcontrib><creatorcontrib>COSKUN TAMER</creatorcontrib><creatorcontrib>OVER CABRERA</creatorcontrib><creatorcontrib>ROBERT CHADWICK CUMMINS</creatorcontrib><creatorcontrib>AKTHAM ABURUB</creatorcontrib><creatorcontrib>KYLE WYNN SLOOP</creatorcontrib><creatorcontrib>ROBERT ANDREW BROWN</creatorcontrib><creatorcontrib>MOHAMED ELSAYED HAMED ELSAYED</creatorcontrib><creatorcontrib>MILATA MARY ABRAHAM</creatorcontrib><creatorcontrib>PHENIL JAYANTILAL PATEL</creatorcontrib><creatorcontrib>THI THANH HUYEN TRAN</creatorcontrib><creatorcontrib>AMITA DATTA-MANNAN</creatorcontrib><creatorcontrib>LAI XIANYIN</creatorcontrib><title>GIP/GLP1 CO-AGONIST COMPOUNDS</title><description>To provide compounds that have agonist activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and are suitable for oral administration.SOLUTION: The present invention provides a compound having a specific amino acid sequence or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
【課題】ヒトグルコース依存性インスリン分泌刺激ポリペプチド（ＧＩＰ）受容体およびグルカゴン様ペプチド－１（ＧＬＰ－１）受容体でアゴニスト活性を有する、経口投与に適した化合物を提供する。【解決手段】特定のアミノ酸配列を有する化合物、またはその薬学的に許容可能な塩による。【選択図】なし</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB19wzQd_cJMFRw9td1dPf38wwOATJ9A_xD_VyCeRhY0xJzilN5oTQ3g5Kba4izh25qQX58anFBYnJqXmpJvFeAkYGRsaG5obm5qaMxUYoAxDohbQ</recordid><startdate>20231205</startdate><enddate>20231205</enddate><creator>QU HONGCHANG</creator><creator>JORGE ALSINA-FERNANDEZ</creator><creator>FRANCIS STAFFORD WILLARD</creator><creator>JAMES LINCOLN WALLIS</creator><creator>COSKUN TAMER</creator><creator>OVER CABRERA</creator><creator>ROBERT CHADWICK CUMMINS</creator><creator>AKTHAM ABURUB</creator><creator>KYLE WYNN SLOOP</creator><creator>ROBERT ANDREW BROWN</creator><creator>MOHAMED ELSAYED HAMED ELSAYED</creator><creator>MILATA MARY ABRAHAM</creator><creator>PHENIL JAYANTILAL PATEL</creator><creator>THI THANH HUYEN TRAN</creator><creator>AMITA DATTA-MANNAN</creator><creator>LAI XIANYIN</creator><scope>EVB</scope></search><sort><creationdate>20231205</creationdate><title>GIP/GLP1 CO-AGONIST COMPOUNDS</title><author>QU HONGCHANG ; JORGE ALSINA-FERNANDEZ ; FRANCIS STAFFORD WILLARD ; JAMES LINCOLN WALLIS ; COSKUN TAMER ; OVER CABRERA ; ROBERT CHADWICK CUMMINS ; AKTHAM ABURUB ; KYLE WYNN SLOOP ; ROBERT ANDREW BROWN ; MOHAMED ELSAYED HAMED ELSAYED ; MILATA MARY ABRAHAM ; PHENIL JAYANTILAL PATEL ; THI THANH HUYEN TRAN ; AMITA DATTA-MANNAN ; LAI XIANYIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2023171775A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>QU HONGCHANG</creatorcontrib><creatorcontrib>JORGE ALSINA-FERNANDEZ</creatorcontrib><creatorcontrib>FRANCIS STAFFORD WILLARD</creatorcontrib><creatorcontrib>JAMES LINCOLN WALLIS</creatorcontrib><creatorcontrib>COSKUN TAMER</creatorcontrib><creatorcontrib>OVER CABRERA</creatorcontrib><creatorcontrib>ROBERT CHADWICK CUMMINS</creatorcontrib><creatorcontrib>AKTHAM ABURUB</creatorcontrib><creatorcontrib>KYLE WYNN SLOOP</creatorcontrib><creatorcontrib>ROBERT ANDREW BROWN</creatorcontrib><creatorcontrib>MOHAMED ELSAYED HAMED ELSAYED</creatorcontrib><creatorcontrib>MILATA MARY ABRAHAM</creatorcontrib><creatorcontrib>PHENIL JAYANTILAL PATEL</creatorcontrib><creatorcontrib>THI THANH HUYEN TRAN</creatorcontrib><creatorcontrib>AMITA DATTA-MANNAN</creatorcontrib><creatorcontrib>LAI XIANYIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>QU HONGCHANG</au><au>JORGE ALSINA-FERNANDEZ</au><au>FRANCIS STAFFORD WILLARD</au><au>JAMES LINCOLN WALLIS</au><au>COSKUN TAMER</au><au>OVER CABRERA</au><au>ROBERT CHADWICK CUMMINS</au><au>AKTHAM ABURUB</au><au>KYLE WYNN SLOOP</au><au>ROBERT ANDREW BROWN</au><au>MOHAMED ELSAYED HAMED ELSAYED</au><au>MILATA MARY ABRAHAM</au><au>PHENIL JAYANTILAL PATEL</au><au>THI THANH HUYEN TRAN</au><au>AMITA DATTA-MANNAN</au><au>LAI XIANYIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GIP/GLP1 CO-AGONIST COMPOUNDS</title><date>2023-12-05</date><risdate>2023</risdate><abstract>To provide compounds that have agonist activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and are suitable for oral administration.SOLUTION: The present invention provides a compound having a specific amino acid sequence or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
【課題】ヒトグルコース依存性インスリン分泌刺激ポリペプチド（ＧＩＰ）受容体およびグルカゴン様ペプチド－１（ＧＬＰ－１）受容体でアゴニスト活性を有する、経口投与に適した化合物を提供する。【解決手段】特定のアミノ酸配列を有する化合物、またはその薬学的に許容可能な塩による。【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2023171775A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | GIP/GLP1 CO-AGONIST COMPOUNDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T15%3A26%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=QU%20HONGCHANG&rft.date=2023-12-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2023171775A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |